Artron Laboratories Inc. Announces Q1 2026 EPS of NT$0.28
Artron Laboratories Inc. announced its Q1 2026 financial results, with EPS of NT$0.28, operating revenue of NT$88 million, and net income after tax of NT$17 million, reflecting steady business performance in the biotechnology and medical sector.
📋 Article Processing Timeline
- 📰 Published: March 1, 2026 at 09:00
- 🔍 Collected: May 14, 2026 at 08:00 (1775h 0m after Published)
- 🤖 AI Analyzed: May 14, 2026 at 08:11 (10 min after Collected)
## Artron Laboratories Inc. Q1 2026 Financial Results Express Report
Company Code: 4133
Company Name: Artron Laboratories Inc.
Industry: Biotechnology and Medical Industry
Fiscal Year/Quarter: Q1 2026
Basic Earnings Per Share (EPS): NT$0.28
Operating Revenue: NT$88 million
Net Income After Tax: NT$17 million
Company Code: 4133
Company Name: Artron Laboratories Inc.
Industry: Biotechnology and Medical Industry
Fiscal Year/Quarter: Q1 2026
Basic Earnings Per Share (EPS): NT$0.28
Operating Revenue: NT$88 million
Net Income After Tax: NT$17 million